Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure

doi:10.12092/j.issn.1009-2501.2022.02.013

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (2): 212-218.doi: 10.12092/j.issn.1009-2501.2022.02.013

Previous Articles Next Articles

Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure

LIU Ping1,2, QIU Bo2, WU Huizhen1,2

1Graduate School of Hebei Medical University, Shijiazhuang 050017, Hebei, China; 2Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051, Hebei, China

Received:2021-11-03 Revised:2022-01-24 Online:2022-02-26 Published:2022-03-09

Abstract

Abstract: Vericiguat is a soluble guanylate cyclase stimulator, acting on nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate pathway. Vericiguat can improve the sensitivity soluble guanylate cyclase sensitivity to nitric oxide, stimulate soluble guanylate cyclase without relying on nitric oxide, leading to increased formation of cyclic guanosine monophosphate , which results in multi-dimensional protection effects for the heart. It provides a new therapeutic approach for patients with heart failure. This review provides an overview of mechanism, preclinical studies, pharmacokinetics, clinical efficacy, drug-drug interactions and limitations of vericiguat.

Key words: vericiguat, heart failure, soluble guanylate cyclase stimulator

CLC Number:

R541.6+1
R96

LIU Ping, QIU Bo, WU Huizhen. Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 212-218.

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua. Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183.
[3]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[4]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[5]	PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
[6]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[7]	CHEN Lifang, WANG Bo, WANG Weirong. Research advances of histone deacetylase 3 in cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 88-97.
[8]	FAN Jianfeng，FANG Yi，ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
[9]	SHEN Lei, WANG Keke, YANG Jingke, ZHAO Juntao, MENG Xiangguang, YUAN Yiqiang. Advances in drugs and genetic pharmacology for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 343-349.
[10]	WEI Zihan,LI Dongbo，YUAN Zheng,LU Ying, YANG Guojie. Clinical trial of sacubitril/valsartan in the treatment of Pulmonary hypertension (PH) due to left heart disease (LHD) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 57-62.
[11]	HUANG Ting, WANG Hegui. Research progress in regulation of heart failure by β-adrenergic-receptor-PKA-AKAP signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 592-596.
[12]	WANG Shibiao, WANG Chengyi, WENG Bin, GUO Xiaofeng, LIN Hai. Comparison of the efficacy of non-invasive USCOM and milrinone in children with severe pneumonia and heart failure and its effect on brain natriuretic peptide levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1402-1407.
[13]	LIU Yu, ZHANG Ying, WANG Ancai. Effect of rhBNP on chronic systolic heart failure combined with diuretic resistance and concentration of TNF-α and NPY [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 814-820.
[14]	WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304.
[15]	LIU Changjiang, WU Yang, SHAO Peipei, LI Shaohua, CHENG Lufeng. Optimization of chronic heart failure model induced by coronary artery ligation in rats with swimming exhaustion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1340-1345.

Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments